The black cellphone-sized device buzzed intently three times. 80 mg/dL, the screen urgently warned in bright red letters on a black background, LOW. Time to take a sip of Gatorade. The insistent ...

FDA classifies this as a Class I recall, which means using the device could result in adverse health effects or death. Dexcom Inc., has recalled its G4 Platinum and G5 Mobile continuous glucose ...

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...

The Dexcom G4 receiver, which will have an "identical" form factor to the forthcoming Bluetooth version. In a call to investors days after its app won FDA approval, Dexcom CEO Kevin Sayer shared some ...

The US Food and Drug Administration (FDA) has approved a new insulin pump/continuous glucose monitor (CGM) product, Tandem's t:slim Insulin Pump and Dexcom G4 PLATINUM CGM System, according to a ...

Dexcom has announced it has received FDA approval of a new continuous glucose monitoring system, according to a news release. The Dexcom G4 PLATINUM system consists of three parts: a sensor, ...

DexCom, Inc.DXCM recently announced the signing of a development agreement with Eli Lilly and Company LLY. Per the agreement, DexCom's flagship continuous glucose monitoring system (CGM) will be added ...

Dexcom, the company behind one of the leading continuous glucose monitor solutions for diabetes patients, has announced today that their “Follow” mobile app—which has long been available on iOS—is now ...

Dexcom, Inc. (NASDAQ: DXCM) issues this press release to supplement its previous customer notification and remind its patients to periodically test the audible alarms and alerts on certain receivers ...

DexCom, Inc. DXCM is well poised for growth on the back of solid international presence and robust product portfolio. The stock has gained 212.8%, compared with the industry’s growth of 14.3% in a ...